PMID- 34294460
OWN - NLM
STAT- MEDLINE
DCOM- 20210930
LR  - 20240402
IS  - 1879-1166 (Electronic)
IS  - 0198-8859 (Print)
IS  - 0198-8859 (Linking)
VI  - 82
IP  - 10
DP  - 2021 Oct
TI  - HLA-DRB1*04 may predict the severity of disease in a group of Iranian COVID-19 
      patients.
PG  - 719-725
LID - S0198-8859(21)00178-6 [pii]
LID - 10.1016/j.humimm.2021.07.004 [doi]
AB  - Human leukocyte antigen (HLA) genes with extreme diversity can make a 
      contribution for individual variations to the immune response against SARS-COV-2 
      infection. This study aimed to explore the distributions of HLA class II alleles 
      frequencies and their relations with disease severity in a group of Iranian 
      COVID-19 patients. This prospective and case-control study was conducted on 144 
      COVID-19 patients including 46 cases with moderate form, 54 cases with severe and 
      44 cases with critical disease. HLA-DRB1 and -DQB1 allele families were 
      determined by PCR-SSP method and compared between three groups of the patients 
      and in comparison to 153 ethnic-matched healthy controls. The patients group 
      showed lower frequencies of HLA-DRB1*15 (OR = 0.57, P = 0.06), DRB1*15 ~ DQB1*05 
      haplotype (P = 0.04) and DRB1*15/DRB1*04 genotype (P = 0.04) in compare with 
      healthy controls. Moderate COVID-19 patients had higher frequencies of 
      HLA-DRB1*04 (P = 0.03), HLA-DRB1*10 (P = 0.05) and DRB1*04/DRB1*11 genotype 
      (P = 0.01). Also, a higher significantly frequency of HLA-DRB1*03 allele group 
      was observed in the critical patients versus controls (P = 0.01). Multiple 
      logistic regression analysis revealed that the presence of DRB1*04 allele group 
      was negatively associated with development of severe and critical disease (OR: 
      0.289, P = 0.005). Our results indicate a possible contribution of some HLA class 
      II alleles in disease severity and clinical features of COVID-19 disease.
CI  - Copyright (c) 2021 American Society for Histocompatibility and Immunogenetics. 
      Published by Elsevier Inc. All rights reserved.
FAU - Ebrahimi, Samaneh
AU  - Ebrahimi S
AD  - Department of Immunology, School of Medicine, Hamadan University of Medical 
      Sciences, Hamadan, Iran.
FAU - Ghasemi-Basir, Hamid Reza
AU  - Ghasemi-Basir HR
AD  - Department of Pathology, School of Medicine, Hamadan University of Medical 
      Sciences, Hamadan, Iran.
FAU - Majzoobi, Mohammad Mahdi
AU  - Majzoobi MM
AD  - Brucellosis Research Centre, Hamadan University of Medical Sciences, Hamadan, 
      Iran.
FAU - Rasouli-Saravani, Ashkan
AU  - Rasouli-Saravani A
AD  - Department of Immunology, School of Medicine, Hamadan University of Medical 
      Sciences, Hamadan, Iran.
FAU - Hajilooi, Mehrdad
AU  - Hajilooi M
AD  - Department of Immunology, School of Medicine, Hamadan University of Medical 
      Sciences, Hamadan, Iran.
FAU - Solgi, Ghasem
AU  - Solgi G
AD  - Department of Immunology, School of Medicine, Hamadan University of Medical 
      Sciences, Hamadan, Iran. Electronic address: gh.solgi@umsha.ac.ir.
LA  - eng
PT  - Journal Article
DEP - 20210713
PL  - United States
TA  - Hum Immunol
JT  - Human immunology
JID - 8010936
RN  - 0 (HLA-DRB1 Chains)
RN  - 0 (HLA-DRB1*04 antigen)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Alleles
MH  - COVID-19/*genetics
MH  - Case-Control Studies
MH  - Female
MH  - Gene Frequency/genetics
MH  - Genotype
MH  - HLA-DRB1 Chains/*genetics
MH  - Haplotypes/genetics
MH  - Histocompatibility Testing/methods
MH  - Humans
MH  - Iran
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - SARS-CoV-2/pathogenicity
MH  - Severity of Illness Index
MH  - Young Adult
PMC - PMC8275473
OTO - NOTNLM
OT  - Alleles
OT  - COVID-19
OT  - HLA-DRB1
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2021/07/24 06:00
MHDA- 2021/10/01 06:00
PMCR- 2021/07/13
CRDT- 2021/07/23 05:45
PHST- 2021/01/10 00:00 [received]
PHST- 2021/07/08 00:00 [revised]
PHST- 2021/07/08 00:00 [accepted]
PHST- 2021/07/24 06:00 [pubmed]
PHST- 2021/10/01 06:00 [medline]
PHST- 2021/07/23 05:45 [entrez]
PHST- 2021/07/13 00:00 [pmc-release]
AID - S0198-8859(21)00178-6 [pii]
AID - 10.1016/j.humimm.2021.07.004 [doi]
PST - ppublish
SO  - Hum Immunol. 2021 Oct;82(10):719-725. doi: 10.1016/j.humimm.2021.07.004. Epub 
      2021 Jul 13.